OTLC

Oncotelic Therapeutics, Inc.

OTCHealthcarePHARMACEUTICAL PREPARATIONS

Insider activity for last month from Oct 16 to Nov 16.

How these metrics are calculated

Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.

Total buying—2 buys
Total selling$00 sales
Net open-market—Buying minus selling
Active insiders1Distinct reporting owners

OTLC transaction history

Newest filings · 20 transactions per page

Latest insider transactions

Form 4 filings from last month.
Newest company filings
InsiderActivityDisclosed valueFiled (ET)
Trieu Vuong
Chair
CHAIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
Director buy
The buyer is identified as a director.
SEC filing ↗
—View disclosure →
Trieu Vuong
Chair
CHAIR
Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner buy
The buyer is a beneficial owner of more than 10% of the company.
Director buy
The buyer is identified as a director.
SEC filing ↗
—View disclosure →

Insider activity report

Calendar-month buckets within the selected date range

Latest filing: Oct 30, 2026

Open-market transaction mix · 2 transactions in the selected period
2 buys100%·0%0 sells

Code A includes awards, grants and other acquisitions; these are not open-market buys. A rolling period can include partial calendar months.

View exact monthly counts and disclosed values
Monthly activity within the selected period; unknown values remain unknown.
MonthBuysSellsAwards (A)Buy valueSell valueNet P/S value
Oct 2026200—$0—
Nov 2026000$0$0$0

Distinct insiders active

Reporting-owner CIKs by month · peak Oct 2026 (1)
Oct 2026: 1 insidersNov 2026: 0 insiders
Oct 2026Nov 2026
1distinct insiders in selected period
Largest insider activity
By absolute net disclosed value · current transaction page
1 insider
  • TV
    Trieu VuongCHAIR · 2 buys · 0 sales · 0 awards (A)
    —last Oct 30
Filing, role and holdings details

Filing-only signals

Deterministic matches in the selected period

Recent filing activity
Most recent 2 transactions on this page · color = transaction code

Filing detail checks

Secondary metrics for the selected period
Largest buy—
Largest sale—
10b5-1 detected0
Amended rows0

Transaction codes

By Form 4 transaction code in selected period
2transactionstxns
  • P · Open-market buys · dominant2 · 100%

Activity by reported role

A joint filing can contribute to multiple roles
CHAIR2

Reported Holdings After

Separated by insider, security, and ownership type

Trieu VuongCommon Stock · Direct
95.5M94.4MOct 28, 2026Oct 29, 2026
95,481,309Oct 29, 2026

These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.

Filing activity heatmap
Current transaction page only · each cell is a filing date · buys green, sells red
1 active days
Oct 16 → Nov 16
LessMore

Oncotelic Therapeutics, Inc. Insider Activity FAQ

SEC Form 4 context

Who recently reported transactions at Oncotelic Therapeutics, Inc.?

Trieu Vuong.

When was the latest reported open-market purchase?

Trieu Vuong reported a buy on Oct 29, 2026 valued at an unknown value. Read the SEC filing.

When was the latest reported open-market sale?

No code-S sale is available for this period.

What is the recent purchase and sale balance?

The net open-market value is unknown because at least one matching code-P or code-S row lacks a value.

Where can I see the original SEC filing?

Every transaction row and latest-activity fact links to its original SEC filing.

What do these Form 4 transaction codes mean?

P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.